Content provided by Aubrey Gordon & Michael Hobbes, Aubrey Gordon, and Michael Hobbes. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Aubrey Gordon & Michael Hobbes, Aubrey Gordon, and Michael Hobbes or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Ozempic
MP3•Episode home
Manage episode 379341829 series 2805106
Content provided by Aubrey Gordon & Michael Hobbes, Aubrey Gordon, and Michael Hobbes. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Aubrey Gordon & Michael Hobbes, Aubrey Gordon, and Michael Hobbes or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Ozempic is being hailed as “the end of the Obesity Epidemic.” This week, Mike and Aubrey dig through the sensational claims. But will they make it past the caveats?
Links:
- How a Canadian scientist and a venomous lizard helped pave the way for Ozempic
- The Discovery and Development of Liraglutide and Semaglutide
- Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor
- Insurers clamping down on doctors who prescribe Ozempic for weight loss
- Ozempic prescriptions can be easy to get online. Its popularity for weight loss is hurting those who need it most
- Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: real-world evidence from a Mediterranean area
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
- Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
- Safety of Semaglutide
- Semaglutide for the treatment of overweight and obesity: A review
- Once-Weekly Semaglutide in Adolescents with Obesity
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
- Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States
- Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data
Thanks to Doctor Dreamchip for our lovely theme song!
80 episodes
MP3•Episode home
Manage episode 379341829 series 2805106
Content provided by Aubrey Gordon & Michael Hobbes, Aubrey Gordon, and Michael Hobbes. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Aubrey Gordon & Michael Hobbes, Aubrey Gordon, and Michael Hobbes or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Ozempic is being hailed as “the end of the Obesity Epidemic.” This week, Mike and Aubrey dig through the sensational claims. But will they make it past the caveats?
Links:
- How a Canadian scientist and a venomous lizard helped pave the way for Ozempic
- The Discovery and Development of Liraglutide and Semaglutide
- Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor
- Insurers clamping down on doctors who prescribe Ozempic for weight loss
- Ozempic prescriptions can be easy to get online. Its popularity for weight loss is hurting those who need it most
- Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: real-world evidence from a Mediterranean area
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
- Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
- Safety of Semaglutide
- Semaglutide for the treatment of overweight and obesity: A review
- Once-Weekly Semaglutide in Adolescents with Obesity
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
- Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States
- Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data
Thanks to Doctor Dreamchip for our lovely theme song!
80 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.